USS Investment Management Ltd Has $3.84 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

USS Investment Management Ltd cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 34.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53,328 shares of the medical equipment provider's stock after selling 28,395 shares during the quarter. USS Investment Management Ltd's holdings in Hologic were worth $3,844,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Worldquant Millennium Advisors LLC lifted its position in shares of Hologic by 16.6% during the fourth quarter. Worldquant Millennium Advisors LLC now owns 214,815 shares of the medical equipment provider's stock valued at $15,486,000 after purchasing an additional 30,645 shares in the last quarter. Woodline Partners LP lifted its position in shares of Hologic by 14.3% during the fourth quarter. Woodline Partners LP now owns 144,072 shares of the medical equipment provider's stock valued at $10,386,000 after purchasing an additional 18,072 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of Hologic by 657.8% during the fourth quarter. Squarepoint Ops LLC now owns 264,800 shares of the medical equipment provider's stock valued at $19,089,000 after purchasing an additional 229,858 shares in the last quarter. Two Sigma Advisers LP raised its position in Hologic by 78.2% in the fourth quarter. Two Sigma Advisers LP now owns 31,000 shares of the medical equipment provider's stock worth $2,235,000 after acquiring an additional 13,600 shares during the period. Finally, Tidal Investments LLC raised its position in Hologic by 38.3% in the fourth quarter. Tidal Investments LLC now owns 21,223 shares of the medical equipment provider's stock worth $1,530,000 after acquiring an additional 5,872 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director now owns 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.88% of the stock is owned by insiders.

Hologic Stock Performance

HOLX traded down $0.46 on Thursday, hitting $63.25. 1,008,438 shares of the company's stock were exchanged, compared to its average volume of 2,239,951. The firm has a market cap of $14.09 billion, a PE ratio of 20.00, a P/E/G ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The stock has a fifty day moving average of $58.09 and a two-hundred day moving average of $66.21. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the firm earned $1.03 EPS. The firm's quarterly revenue was down 1.2% on a year-over-year basis. On average, research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HOLX. William Blair reaffirmed an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Evercore ISI decreased their price objective on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research note on Tuesday. Citigroup cut their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada dropped their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Twelve analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $77.42.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.